Bull
$380.94
Scenario price
$310.360
+13.873 (+4.47%)At close
Willis Towers Watson Public Limited Company is a global advisory, brokering and solutions company that provides data-driven, insight-led solutions in the areas of people, risk and capital. Its segments include Health, Wealth & Career (HWC) and Risk & Broking (R&B). The HWC segment provides an array of advice, brokering, solutions and technology for employee benefit plans, institutional investors, compensation and career programs, and the employee experience overall. Its R&B segment provides a range of risk advice, insurance brokerage and consulting services to clients globally, ranging from small businesses to multinational corporations. The segment comprises two primary businesses: its corporate risk and brokering and our insurance consulting and technology businesses. It also specializes in private equity secondaries investing, delivering innovative portfolio construction, risk management, and client solutions. It provides pension and savings products through a mobile application.
Willis Towers Watson PLC is currently priced at $296.26, with a forward P/E ratio of 17.42, indicating it is fairly valued compared to its earnings potential. However, the recent downgrade from Mizuho, reducing the price target from $380 to $349, reflects cautious sentiment among analysts. Additionally, the RSI of 54.63 suggests the stock is neither overbought nor oversold, indicating a neutral momentum. The primary risk is the recent performance trend, with a year-to-date change of -9.20%, which may deter new investors.
BofA
$365
2026-10-12
BofA
2026-10-12
Price Target
$365
Keefe Bruyette
$360
2026-10-12
Keefe Bruyette
2026-10-12
Price Target
$360
Mizuho
$349
2026-10-07
Mizuho
2026-10-07
Price Target
$349
Barclays
$332
2026-10-07
Barclays
2026-10-07
Price Target
$332
Morgan Stanley
$310
2026-10-06
Morgan Stanley
2026-10-06
Price Target
$310
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Significant Rise in U.S. Health Insurance Costs Expected

U.S. Commercial Insurance Prices Continue to Rise

Willis Appoints New Head of Asia Pacific Captive Solutions

WTW Becomes Official Insurance Partner of Barclays WSL

Baupost Group Exits Entire Stake in Vaxcyte and WTW
Willis Towers Watson Public Limited Company is a global advisory, brokering and solutions company that provides data-driven, insight-led solutions in the areas of people, risk and capital. Its segments include Health, Wealth & Career (HWC) and Risk & Broking (R&B). The HWC segment provides an array of advice, brokering, solutions and technology for employee benefit plans, institutional investors, compensation and career programs, and the employee experience overall. Its R&B segment provides a range of risk advice, insurance brokerage and consulting services to clients globally, ranging from small businesses to multinational corporations. The segment comprises two primary businesses: its corporate risk and brokering and our insurance consulting and technology businesses. It also specializes in private equity secondaries investing, delivering innovative portfolio construction, risk management, and client solutions. It provides pension and savings products through a mobile application. It operates in the Financials sector (INSURANCE AGENTS, BROKERS & SERVICE industry).
Willis Towers Watson PLC is currently priced at $296.26, with a forward P/E ratio of 17.42, indicating it is fairly valued compared to its earnings potential. However, the recent downgrade from Mizuho, reducing the price target from $380 to $349, reflects cautious sentiment among analysts. Additionally, the RSI of 54.63 suggests the stock is neither overbought nor oversold, indicating a neutral momentum. The primary risk is the recent performance trend, with a year-to-date change of -9.20%, which may deter new investors.
3 analysts cover WTW: 1 rate it Buy, 2 Hold and 0 Sell. The average price target is 365.00.
No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.